Michal Kuchar

Psychopharmacology Researcher

Data updated

Papers

14 publications

Trials

0 clinical trials

Research Footprint

Michal Kuchar appears in 14 tracked papers (2018–2026), most studied alongside Psilocybin, Placebo and 5-MeO-DMT, across Microdosing, Creativity and Depressive Disorders.

Most-cited paper: A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms (196 citations).

Frequent co-authors: Tomáš Páleníček, František Tylš and Martin Brunovský.

Publication Landscape

How the 14 papers Blossom tracks for Michal Kuchar line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.

How has Michal Kuchar's publishing grown?

Sourced

Tracked papers by publication year. Click a year for the running total.

3papers published in 2021

+200% vs 2020

6 published by 2021

Browse papers

Don't read as total output: only the 14 of 14 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.

What does Michal Kuchar publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.

Where does Michal Kuchar publish?

Sourced

Tracked papers per journal. Orange marks the most-used journal.

Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.

Background & Research

Michal Kuchar (publishing frequently as M. Kuchar) is a psychopharmacology researcher whose work sits at the intersection of experimental and naturalistic studies of classical and novel psychedelics. He has co‑authored multiple empirical investigations into microdosing effects on cognition and creativity, naturalistic inhalation studies of toad‑derived 5‑MeO‑DMT reporting sustained changes in wellbeing and mindfulness, and studies linking single psilocybin doses to long‑term increases in mindfulness together with proportional changes in neocortical 5‑HT2A receptor binding. Kuchar's collaborations span behavioural, pharmacological and neuroimaging groups, and his papers contribute both primary data and methodological reflection on transparency and reproducibility in the rapidly expanding field of psychedelic science.

Kuchar's contributions emphasise pragmatic, field‑relevant approaches (open‑label and naturalistic designs) alongside more controlled neurobiological investigations, positioning him as a bridge between laboratory neuropharmacology and real‑world psychedelic experiences. He has been involved in multi‑author projects addressing microdosing, the phenomenology of high‑intensity compounds (such as 5‑MeO‑DMT), and the potential utility of psychedelics as tools for modelling altered states of consciousness and therapeutic mechanisms.

Key Impact

Notable for contributions to empirical and naturalistic studies of psychedelic compounds—particularly microdosing, psilocybin and 5‑MeO‑DMT—and for work on methodological transparency in psychedelic research.

14

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

36 collaborators· click a node to visit their profile

Full network →

Collaboration Network

See Michal Kuchar's full collaboration network, shared papers, and research connections.

Affiliations

Institutions, companies, and organisations Michal Kuchar is associated with.